6h
Arrowhead Pharmaceuticals (ARWR) Is Up 48.1% After First FDA Approval for siRNA Rare Disease Therapy
In November 2025, Arrowhead Pharmaceuticals announced that the U.S. FDA approved REDEMPLO (plozasiran) as the first and only siRNA treatment for adults with familial chylomicronemia syndrome, ...
A drug safety group has delivered a positive analysis for a Sarepta Therapeutics-licensed RNA medicine, with the same study ...
Pharmaceutical Technology on MSN
Arrowhead nets first commercial win as siRNA drug garners FDA approval
Redemplo’s approval in familial chylomicronemia syndrome places the drug in competition with Ionis’ Tryngolza.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using ...
Despite considerable challenges, RNA interference (RNAi) as a therapeutic strategy continues to draw excitement and scrutiny. Two recent meetings—Select Biosciences’ “RNAi and miRNA World Congress” ...
Clinical translation of therapies based on small interfering RNA (siRNA) is hampered by siRNA’s comprehensively poor pharmacokinetic properties, which necessitate molecule modifications and complex ...
The current coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has challenged healthcare facilities globally. Even though the FDA ...
Tumours can avert an immune response and boost their own growth by inducing the expression of immunosuppressive, angiogenic and growth factors by neighbouring cells. Reporting in Nature Biotechnology, ...
Announcing a new article published for the BIO Integration journal. In this review article the authors Shuwen Cao, Chunhao Lin, Shunung Liang, Chee Hwee Tan, Xiaoding Xu, and Phei Er Saw from Sun ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback